The role of angiotensine receptor blocker treatment in patients with rheumatoid arthritis: evaluate of endothelial function

The role of angiotensine receptor blocker treatment in patients with rheumatoid arthritis: evaluate of endothelial function - Efficacy of angiotensine receptor blocker for patient with rheumatoid arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008536

Enrollment

Registered

2012-08-01

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Oral administration of angiotensine receptor blocker

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The case of rheumatoid arthritis with hypertension

Exclusion criteria

Exclusion criteria: The case who in disqualified by the physician

Design outcomes

Primary

Measure	Time frame
Endothelial function after 8 weeks treatment of angiotensine receptor blocker	—

Countries

Japan

Contacts

Public ContactTAKEO SAKUTA

Kawasaki Medical School Department of Rheumatology

sakuta@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026